Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Medline is poised for future success with its strong domestic market presence, diversified product portfolio, and efficient supply chain capabilities. Despite some challenges and uncertainties in the healthcare industry, Medline remains a top provider for major US health systems and continues to expand its reach globally through investments in technology and international expansion. Furthermore, MDLN's experienced leadership team and focus on driving growth through acquisitions and brand expansion make it a stable and promising investment for the long term.

Bears say

Medline is positioned well within the medical product market, but faces significant competition as a solely US-based company. Its Prime Vendor relationships incentivize customers to purchase more Medline Brand products, but only represent ~35% of its total sales currently. In order to drive future growth and maintain its competitive edge, Medline will need to continue investing in its Prime Vendor and Supply Chain Solutions, as well as explore potential acquisitions and international expansion opportunities.

Medline Inc (MDLN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 23 analysts, Medline Inc (MDLN) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.